ArticleFrontiers in oncology2026
Racial disparities in breast cancer subtypes, recurrence, and survival: a longitudinal cohort analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Racial disparities in breast cancer subtype distribution and clinical outcomes are well documented, yet integrated longitudinal analyses examining subtype, recurrence, and survival within standardized cohorts remain limited. This study examines race-associated differences in breast cancer subtypes, recurrence patterns, and survival outcomes using a retrospective longitudinal cohort. Methods: A total of 922 women from the Duke Breast Cancer MRI dataset were analyzed. Race was categorized Results: The median age at diagnosis (in years) was 52.2 (IQR 45.4-60.8), with Black patients presenting at younger median ages compared with White patients (p< 0.001). Black women had the highest prevalence of triple-negative breast cancer (29.6%). Sixty-five (47.1%) of black patients presented with stage III Nottingham grade at presentation (P< 0.001). The overall recurrence rate was 9.4%, and mortality rate was 6.7%, with no statistically significant difference between groups. Discussion: Black patients demonstrated a higher prevalence of aggressive tumor biology at presentation; however, survival differences were attenuated after multivariable adjustment. Given the limited number of mortality events, adjusted survival estimates should be interpreted cautiously, as these findings underscore the need for larger, prospective studies integrating genomic, imaging, and socioeconomic data to better define drivers of outcome disparities in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.